

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2009-2013

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	30.7	87.8	(57.9-127.8)	Male	18	19.2	93.6	(55.4-147.9)
Female	5	10.8	46.3	(14.9-108.2)	Female	15	14.5	103.1	(57.7-170.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	5.5	162.8	(74.3-309.2)	Male	7	6.1	115.7	(46.3-238.3)
Female	4	4.5	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	21	17.0	123.7	(76.6-189.1)
Female	127	115.4	110.0	(91.7-130.9)	Female	14	14.7	95.0	(51.9-159.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.8	nc	(nc-nc)	Male	12	13.1	91.9	(47.4-160.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	32.0	96.9	(65.8-137.5)	Female	7	10.2	68.4	(27.4-141.0)
Female	27	31.7	85.3	(56.2-124.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	10.5	113.8	(58.7-198.8)
Male	3	7.8	nc	(nc-nc)	Female	10	10.6	94.5	(45.2-173.8)
Female	0	2.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	97	94.8	102.3	(83.0-124.8)
Male	1	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.7	nc	(nc-nc)	Male	3	7.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	4.1	nc	(nc-nc)
Male	20	15.6	128.0	(78.2-197.7)	<u>Testis</u>				
Female	5	9.3	53.5	(17.2-124.9)	Male	3	3.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.5	nc	(nc-nc)	Male	12	6.9	172.9	(89.2-302.0)
Female	1	1.4	nc	(nc-nc)	Female	28	20.7	135.5	(90.0-195.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	11.9	142.6	(83.0-228.3)	Female	31	25.9	119.6	(81.3-169.8)
Female	7	8.5	82.7	(33.1-170.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	394	385.3	102.2	(92.4-112.9)
Male	10	10.0	100.1	(47.9-184.1)	Female	392	394.2	99.5	(89.8-109.8)
Female	3	3.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	40	54.5	73.4	(52.5-100.0)					
Female	63	58.3	108.1	(83.1-138.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;